Apeiron strikes again


Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by stimulating the immune system. The transaction follows in the wake of other successful in-licensing deals that Apeiron has completed in the last six months. The collaboration includes an option for Apeiron to enter into a worldwide, exclusive licensing agreement with the Cleveland Clinic relating to the compounds, and a research agreement sponsored by Apeiron relating to these compounds and approach. The approach involves tyrosine phosphatase inhibitors (TPI) inhibiting SHP-1, a protein tyrosine phosphatase that is a key negative regulator of immune cell activation. Inhibition of SHP-1 leads to activation of the immune system to combat cancer. Apeiron CEO Hans Loibner called the deal a “great collaboration for Apeiron,“ adding that he regards the compounds developed at the Cleveland Clinic as “an attractive opportunity, since they are designed to activate the patient’s own immune system.” Loibner has been a specialist for immune therapies in oncology for more than twenty years. Apeiron will also close a financing round to fund the development of its clinical pipeline.



Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria


Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...



Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...



Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...



Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...



Austrian vaccine developer Intercell AG (Vienna) has a new Chief Business Officer. At the beginning of October, Staph Leavenworth Bakali quit Intercell’s supervisory board and joined its management board with key responsibilities...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues